Status:
UNKNOWN
The Effect of Erythropoietin Usage in Renal Function After Kidney Transplantation, in Early Phase, in Contrast to Placebo Group
Lead Sponsor:
Labbafinejhad Hospital
Collaborating Sponsors:
Shahid Beheshti University of Medical Sciences
Conditions:
Transplantation, Kidney
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The study hypothesis is that erythropoietin usage after kidney transplantation, in early phase, can improve the outcome for patients and their graft increasing patient and graft survival.
Eligibility Criteria
Inclusion
- Hb: \>8 and \<10 gr/dl
- Age: \>18 and \<55 years
- Cholesterol: \<300 mg/dl
- Triglyceride: \<400 mg/dl
- First Transplantation
- Protocol of Immunosuppression: CSA + MMF + Prednisolone
- Systolic BP: \<14
- Diastolic BP: \<9
Exclusion
- History of specified cardiac disease
- Second Transplantation or more
- Hb: \<7gr/dl
- The patient needs to infusion of blood
- Evidence of local or systemic infection, at the time of EPO injection
- Presence of ATN / DGF after transplantation
- Presence of emergent hypertension
- High risk patients ( Like; PRA\>50%)
- Past history of hypersensitivity
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2009
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00617474
Start Date
March 1 2008
End Date
March 1 2009
Last Update
March 28 2008
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.